50 results
6-K
EX-99.2
AUTL
Autolus Therapeutics plc
3 Dec 18
Autolus Therapeutics Presents Initial AUTO3 Clinical Data from Phase 1/2
9:15pm
expression of two subtypes of the T cell receptor beta chain: AUTO4 targets TRBC1, while another of the company’s product candidates in development, AUTO5 … , targets TRBC2. Normal T cells contain both TRBC1 and TRBC2 compartments, whereas T cell lymphoma cells are derived from mature cells and express only
6-K
EX-99.3
AUTL
Autolus Therapeutics plc
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm
candidate for multiple myeloma, which comprises two CARs for the multiple myeloma targets, BCMA and CD19. In collaboration with UCL, the Company … MAGNETO Study AUTO6NG contains a CAR that targets GD2 alongside additional programming modules to enhance the activity and persistence. UCL has
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
14 Mar 24
Results of Operations and Financial Condition
12:32pm
CARs for the multiple myeloma targets, BCMA and CD19. Initial data from the MCARTY Phase 1 study in multiple myeloma presented at ASH in December 2023 … in Neuroblastoma – Phase 1 MAGNETO Study AUTO6NG contains a CAR that targets GD2 alongside additional programming modules to enhance the activity
6-K
EX-99.3
AUTL
Autolus Therapeutics plc
4 May 23
Index to Condensed Consolidated Financial Statements
4:04pm
for multiple myeloma, which comprises two independent CARs for the multiple myeloma targets, BCMA and CD19. In collaboration with UCL, the Company initiated … a study in Q1 2022. Patients continue to be enrolled and initial data is expected in 2023. AUTO6NG in Neuroblastoma AUTO6NG contains a CAR that targets
6-K
EX-99.3
AUTL
Autolus Therapeutics plc
3 Aug 23
Index to Condensed Consolidated Financial Statements
4:32pm
CARs for the multiple myeloma targets, BCMA and CD19. In collaboration with UCL, the Company initiated a study in Q1 2022. Patients continue … to be enrolled and initial data is expected by the end of 2023. AUTO6NG in Neuroblastoma o AUTO6NG contains a CAR that targets GD2 alongside additional
8-K
EX-99.1
d9gmc5sx
11 Dec 23
Regulation FD Disclosure
8:31am
6-K
EX-1
wqz864rf3726u2
1 Jul 22
Current report (foreign)
5:15pm
10-K
EX-10.12
qgii3euli2l4ntumlg16
21 Mar 24
Annual report
4:55pm
6-K
EX-1
q0plwbr69qq2rd512g
30 Jun 21
Annual Report and Accounts
6:05am
6-K
EX-1
49fmobtiuvr6a
15 Mar 19
Annual Report and Accounts
5:26pm
6-K
EX-99.1
gevngfwojq3lbmtoi
3 Dec 18
Autolus Therapeutics Presents Initial AUTO3 Clinical Data from Phase 1/2
9:15pm
6-K
EX-1
t3oc 475t
26 May 20
Current report (foreign)
4:31pm
F-1/A
2gfwpzqel3l5psmko5
8 Jun 18
Registration statement (foreign) (amended)
6:25am
F-1/A
wgl1g63lwv 9x0
19 Jun 18
Registration statement (foreign) (amended)
8:05am
424B4
zw9 nfomfaruo
22 Jun 18
Prospectus supplement with pricing info
4:02pm
F-1/A
rsz fzknp
10 May 18
Registration statement (foreign) (amended)
5:19pm
F-1
s70g9f nrz0
7 May 18
Registration statement (foreign)
4:45pm
8-K
mz3lpx6mm
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
6-K
EX-99.2
guhlov4
4 May 23
Index to Condensed Consolidated Financial Statements
4:04pm
6-K
EX-99.1
kcl hxi4tr
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm